Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial.

Objective: To determine the positivity rate of congenital cytomegalovirus (cCMV) testing among universal, hearing-targeted CMV testing (HT-cCMV) and delayed targeted dried blood spot (DBS) testing newborn screening programs, and to examine the characteristics of successful HT-cCMV testing programs.

Study Design: Prospective survey of birth hospitals performing early CMV testing.

Setting: Multiple institutions.